Bone morphogenetic protein 6 (BMP6) has been suggested as an important local factor capable of modulating the stimulatory actions of follicle-stimulating hormone in granulosa cells in vitro. The objective of this experiment was to determine the effect of direct ovarian infusion of BMP6 (2 lg/h) on ovarian function in ewes with an autotransplanted ovary. Treated ewes (n ¼ 6) and vehicle-treated controls (n ¼ 6) were infused during the early follicular phase, between 12 and 24 h after luteal regression, and ovarian response was determined by collection of samples of ovarian venous blood and transdermal ultrasound. In the absence of any change in circulating gonadotropins or in the antral follicle population, BMP6 infusion resulted in acute but transient increases in ovarian inhibin A, androstenedione, and estradiol secretion (P , 0.05) during the second half of the infusion period. Thereafter, treated animals had an advance in the time of the LH surge by around 10 h (43.3 6 2.8 h in treated vs. 53.3 6 2.7 h in controls; P , 0.05) and smaller preovulatory follicles (4.1 6 0.2 mm in treated vs. 5.3 6 0.1 mm in controls; P , 0.01), which gave rise to smaller corpora lutea (9.5 6 0.8 mm in treated vs. 11.7 6 0.6 mm in controls; P , 0.05). There was, however, no effect of infusion on ovulation rate. Despite the changes in the size of the ovulatory follicles, when the hormonal data were aligned to the time of the luteinizing hormone surge, there were no differences in preovulatory estradiol, androstenedione, or inhibin A between groups. This study therefore provides strong in vivo evidence to support the hypothesis that BMP6 is an important local regulator of ovarian function and that alterations in BMP6 cellular signaling may explain some of the effects of the FecB mutation in inducing precocious maturation of ovulatory follicles.
INTRODUCTION
Ovarian folliculogenesis is a lengthy and intricately regulated process marked by dramatic proliferation and precisely orchestrated differentiation of both the somatic and germ cell elements. Although the latter stages of follicle development are primarily regulated by the pituitary gonadotropins (follicle-stimulating hormone [FSH] and luteinizing hormone [LH] ), there is now strong evidence that this process relies heavily on complex actions and interactions between locally produced hormones and growth factors [1, 2] . The orderly, stage-specific expression of these somatic and oocytederived factors at the correct time, or ''intrafollicular cascade,'' is thought to be essential for the development of the follicle to an ovulatory size, the production of an ovulatory signal, and the release of a fully developmentally competent oocyte in response to that signal. During the gonadotropin-responsive and gonadotropin-dependent stages of follicle development, it has been postulated that these local factors regulate the sensitivity of follicular somatic cells to gonadotropins and are therefore considered to be central to the mechanism of follicle selection and the control of ovulation rate [1, 3, 4] .
The bone morphogenetic proteins (BMPs) are members of the transforming growth factor-beta (TGF-b) superfamily of peptides [5, 6] , which have been implicated recently in the local regulation of ovarian follicular development [2, [7] [8] [9] . The importance of this putative regulatory system in species where the ovulatory quota is rigorously controlled has been highlighted by recent findings showing that naturally occurring mutations in the BMP pathways can result in marked perturbations in ovarian function in prolific breeds of sheep. Thus, mutations in both BMP15 and the closely related GDF9 [10] result in increases in normal ovulation rates and litter sizes in heterozygotes, whereas homozygotes are sterile [11] . In contrast, the Booroola or FecB phenotype has been found to be due to a point mutation in the kinase domain of the BMP receptor type 1B (BMPR1B) and results in a deregulation of the follicle-selection mechanisms with the ''precocious'' development of a large number of small antral follicles, leading to greatly increased ovulation rate and multiple births [12] [13] [14] [15] . Subsequent work has shown that the same mutation occurs in other prolific breeds of sheep, including the Garole, Javanese, Hu, and Han sheep [16, 17] .
Studies on the ovarian physiology of the BMP system in sheep have shown marked similarities to those observed in polyovular rodents [7] , although there are species differences. The TGF-b superfamily members signal via a heteromeric receptor complex consisting of a type I and a type II receptor serine/threonine kinase. Upon ligand binding, the type II receptor recruits the non-ligand-binding type I receptor into the complex, resulting in phosphorylation of signaling pathway effector proteins called Smads [18] . In sheep, expression of both BMPR1B and BMPR1A type 1 receptors and the type 2 BMP receptors has been observed in ovarian somatic cells across all stages of folliculogenesis [19] . Similarly, specific expression of mRNA and/or protein for BMP6 [20, 21] , BMP15 [10] , GDF9 [20] , and AMH [22] has been detected in either the oocyte or somatic cells of ovarian follicles. Further, with the exception of AMH, which has its own type 2 receptor (AMHR2), there is marked promiscuity in the ligands with which the receptors will interact. Therefore, although BMP6, BMP15, and AMH may signal through BMPR1B type 1 receptor, BMP6, BMP15, and GDF9 can all use BMPR2 as their type 2 receptor.
In the rodent, cell culture studies with granulosa cells have shown that BMP6 lacks mitogenic activity and inhibits FSHstimulated progesterone production but has no effect on estradiol production [23, 24] . In contrast, in sheep, although BMP6 has also been observed to be weakly mitogenic [21] and a potent inhibitor of progesterone production [25, 26] , BMP6 stimulates FSH-induced estradiol and inhibin A production and exhibits a strong interaction with insulin-like growth factor (IGF1) in augmenting the differentiative actions of FSH [21] . Similarly, in cattle, BMP6 has been reported to increase both basal and IGF1-stimulated estradiol and inhibin A production by cultured granulosa cells [27] . In terms of thecal cell function, doses of BMP6 that are effective at stimulating estradiol in granulosa cells (5-50 ng/ml) inhibit LH-stimulated androstenedione (A4) production in both sheep [21] and cattle [28] , whereas lower doses (0.005-0.05 ng/ml) stimulate both theca cell proliferation and total A4 production in sheep [21] . Importantly, in parallel investigations using somatic cells from ewes carrying the FecB mutation to the BMPR1B receptor, the responsiveness of both granulosa and theca cells from FecB mutants to stimulation with BMP6 was altered compared with wild-type animals, and these changes were consistent with the profound effect of the FecB mutation in inducing precocious maturation of ovarian follicles [21] .
The existing evidence therefore supports the hypothesis that BMP6 can control ovarian function by directly modulating the sensitivity of ovarian somatic cells to gonadotropic stimuli (FSH and LH). However, this evidence is based on cell culture studies which, particularly in domestic ruminants, are subject to methodological influences [15, 29, 30] , and it is significant that in mice, loss-of-function homozygotes produced by targeted deletion of BMP6 are fertile, with normal-sized litters [31] . In the present experiment, we have used ewes with ovarian autotransplants to examine the in vivo effects of BMP6 on ovarian function. This experimental model allows the infusion of test substances, such as locally active growth factors [3, 32] or hormones [33, 34] , directly into the ovary to expose follicular cells to high local concentrations. Further, the preparation allows repeated collection of ovarian venous blood from conscious animals and transdermal ultrasound scanning of the ovary, thus facilitating the assessment of the effect of treatment on ovulatory follicle development.
MATERIALS AND METHODS

Experimental Animals
Experiments performed here in which live animals were used were done so under project license by the Home Office of the UK government after approval by the Animal Welfare and Ethics Committees of both the University of Nottingham and University of Edinburgh. Mature Border Leicester Merino cross ewes with ovarian autotransplants [32] in which the surgery was performed at least 5 yr previously were used for this experiment. The experiment was carried out during the breeding season (November), and estrous cycles were synchronized using intravaginal progestagen (medoxy-progesterone-acetate)-impregnated sponges (Dunlop, Dumfries, U.K.) that were inserted for 10 days, with an injection of cloprostenol (Estrumate; Intervet, Cambridge, U.K.) at the time of sponge withdrawal (0 h). In both experiments, the absence or presence of estrous behavior prior to sponge insertion was confirmed by inclusion of a keeled Border Leicester ram within the flock.
On the day prior to the start of blood sampling, all animals had cannulae inserted into both jugular veins and the carotid artery as described previously [32] . After cannulation, all sheep were placed in metabolism crates in ventilated rooms and treated prophylactically with antibiotics (3 ml i.m. every 3 days; Clamoxil; SmithKline Beecham) and heparin (5000 IU i.v. every 12 h; Leo Laboratories, Aylesbury, U.K.). The sheep were well habituated to these housing conditions and frequent handling.
Ovarian Arterial Infusion
Recombinant human BMP6 (R & D Systems Inc., Minneapolis, MN) was prepared as a solution of 0.67 lg/ml in 0.9% (w/v) saline with 0.1% (v/v) normal sheep plasma and sterilized by filtration through a 0.22-lm filter. This solution was infused into the carotid artery using syringe-driven pumps fitted with plastic 50-ml syringes at a flow rate of 3 ml/h to give nominal BMP6 infusion rates of 2 lg/h. Blood flow was directed to the ovary by occlusion of the carotid artery cranial to ovarian carotid arterial anastomosis using a pediatric sphygmomanometer (Downs Surgical, Mitcham, U.K.) inflated to a pressure of 200 mm Hg, as described previously [32] .
Experimental Design
A schematic outline of the experimental design is presented in Figure 1 . Arterial infusion was performed during a 12-h period during the early follicular phase, 12 to 24 h after prostaglandin-induced luteal regression. This time period was chosen because previous studies have shown that this period is when final selection of the ovulatory follicles normally occurs in these animals [35] . The two treatment groups were 1) vehicle-only controls (n ¼ 6) and 2) BMP6-treated animals at 2 lg/h (n ¼ 6). During the period of the ovarian infusion, samples of ovarian venous blood (5 ml) were collected at hourly intervals. In addition, there were three periods of more frequent blood sampling (10-min intervals for 2.5 h) that were designed to examine the effect of infusion on the pulsatile pattern of pituitary LH release and ovarian estradiol secretion. These were carried out immediately prior to infusion (À3 to À0.5 h relative to start infusion), during the infusion (5-7.5 h), and at the end of the infusion (10-12.5 h). After the infusion, samples of ovarian and jugular venous blood were collected at four hourly intervals until 60 h after sponge withdrawal to determine the effect of treatment on the timing and characteristics of the preovulatory steroid and gonadotropin surges. Finally, jugular venous samples (5 ml) were taken every day for the 7 days after the end of the intensive experimental period to assess postovulatory luteal function.
Hormone Assays
Blood samples were centrifuged at 48C and 3000 3 g for 20 min to obtain plasma, which was stored at À208C until assay. Estradiol [32] , LH [36] , FSH FIG. 1. Schematic diagram of experimental design. Luteal regression was induced by injection of cloprostenol (PG) at the time of sponge withdrawal on Day 10 of the cycle (0 h). Ovarian arterial infusion of rhBMP6 (2 lg/h; n ¼ 6) or vehicle (n ¼ 6) was performed from 12 to 24 h after luteal regression (striped horizontal bar). During the infusion period, samples of ovarian venous blood (5 ml) were collected at hourly intervals (heavily dotted horizontal bar) and thereafter at four hourly intervals until 60 h after luteal regression (lightly dotted horizontal bar). In addition, there were three periods of more frequent blood sampling (10-min intervals for 2.5 h; solid horizontal bars) immediately prior to infusion (À3 toÀ0.5 h relative to start infusion), during the infusion (5-7.5 h), and at the end of the infusion (10-12.5 h). Idealized profiles show pattern of progesterone (dotted line), estradiol (dashed line), and LH (solid line) expected in untreated animals.
[32], A4 [32] , inhibin A, and progesterone concentrations [37] in ovarian and jugular venous plasma were determined by radioimmunoassay as described previously. All assays had intraassay and interassay coefficients of variation of less than 10% and 15%, respectively.
Ovarian Scanning Procedure
To estimate effects of infusion on the ovarian follicle population and corpora lutea, all animals were scanned immediately prior to and after infusion, and at 12-h intervals after infusion until the end of the intensive blood sampling period at the expected time of the LH surge (60 h after sponge withdrawal). In addition, the ovaries of all animals were scanned on Day 7 of the subsequent luteal days to determine the presence, size, and number of corpora lutea. Transdermal scanning was performed as described previously [35] using a realtime Aloka 500 ultrasound scanner with a linear 7.5-MHz transducer probe (Dynamic Imaging, Livingston, U.K.) and recorded onto videotape. The position, size, and area of all visible follicles and corpora lutea at each scan in each animal were subsequently determined using NIH Image (National Institutes of Health, Bethesda, MD) image analysis software.
Statistical Analyses
Hormone profile data was analyzed using repeated-measures ANOVA, with all hormone data being log transformed prior to statistical analysis. Because of significant between-animal variation, inhibin A concentrations during BMP6 infusion (Fig. 2) were expressed as a percentage relative to the preinfusion values prior to analysis. The characteristics of pulsatile LH and estradiol secretion were determined using the Munro pulse analysis program (Zaristow Software, East Lothian, U.K.). Analysis of pulse characteristics and follicle and corpus luteum size was performed by unpaired t-test. Because BMP6 infusion resulted in an earlier occurrence of the LH surge, the hormone profiles during the postinfusion period were normalized to the peak of the preovulatory LH surge prior to analysis. Further, determination of the size of the preovulatory follicle was made by retrospective analysis of videotaped scans using images obtained from the nearest scan performed prior to the LH surge in each animal.
RESULTS
Acute Effect of BMP6 Infusion
The acute effect of BMP6 infusion on ovarian hormone production, determined from hourly samples of ovarian venous blood, are summarized in Figure 2 , and profiles from individual animals for the entire experimental period are also presented in Figure 3 . There were no differences between treatment groups in any hormones measured during the preinfusion period (À3 to 0 h) or during the first 6 h of treatment. From 6 to 11 h of infusion, there was a transient rise in ovarian inhibin A production in treated animals, and this differed significantly from vehicle-infused controls at the 7-, 8-, and 9-h time points (P , 0.05; Fig. 2) . Similarly, ovarian A4 production increased transiently between 8 and 11 h of infusion, and this differed significantly from vehicle-infused controls at the 9-and 10-h time points (P , 0.05; Fig. 2 ). Finally, estradiol secretion deviated from controls after around 6 h of infusion, and this differed significantly from controls from the 10-h time point until the end of the infusion period at 12 h (P , 0.05; Fig. 2) . However, by the next time point at 16 h, mean estradiol levels in treated ewes had returned to preinfusion values although, as illustrated by the individual profile for a treated ewe presented in Figure 3 , ovarian estradiol, A4, and inhibin A were depressed in this ewe for 8-12 h in the postinfusion period before increasing rapidly prior to the occurrence of the LH surge. Luteinizing hormone and FSH concentrations did not differ from controls across the infusion period (Table 1) . Similarly, there was no difference between the number and size of the antral follicle population before (controls, 8.3 6 1.1 small [,3.5 mm] and 3.0 6 0.5 large [!3.5 mm]; treated, 7.2 6 0.4 small and 2.7 6 0.3 large) or after (controls, 7.0 6 1.0 small and 2.8 6 0.5 large; treated, 6.3 6 0.2 small and 2.7 6 0.2 large) infusion.
The stimulatory effect of BMP6 on ovarian estradiol secretion was more evident from the pulsatile pattern of ovarian estradiol secretion determined from periods of intensive blood sampling. There were no differences in pulsatile estradiol secretion between controls and treated animals in the preinfusion period (data not shown), but from 5 to 7.5 h (Fig. 4A ) and 10 to 12.5 h (Fig. 4B) of infusion, treated animals had higher (P , 0.05) pulse peak heights and pulse amplitudes compared with controls, but no differences in pulse nadir. There were no differences between treatments in the pulsatile pattern of LH secretion during these intensive sampling periods (Table 1) .
Subsequent Effects of BMP6 Infusion
Despite the transient nature of the responses obtained to intraovarian infusion of BMP6, the occurrence of the preovulatory LH surge was 10 h earlier in treated animals (43.3 6 2.8 h after luteal regression) than in vehicle-treated controls (53.3 6 2.7 h; P , 0.05). As illustrated in Figure 3 , individual treated animals exhibited a decline in ovarian hormone secretion in the period (8-12 h) after infusion and then recovered rapidly to exhibit precocious peaks of estradiol, A4, and inhibin A secretion that preceded the preovulatory LH surge in an apparently normal way (Fig. 5) . Because of the slightly different timing of these events, the mean data for this period are relatively confused, but when the hormonal data derived from four hourly blood samples are aligned to the time of the LH surge (Fig. 5) , there were no statistically significant differences in the magnitude or duration of the coincident LH and FSH surges or the preceding peaks in estradiol and A4 production. The estradiol surge, however, appeared to be somewhat less acute in treated animals and had fallen significantly lower then controls at the À4-h time point. Inhibin A levels did not vary in either experimental group in the period before the LH surge (Fig. 5) . The earlier LH surge in treated ewes meant that ultrasound data beyond around 48 h after luteal regression (i.e., 24 h after infusion) could not be directly compared, but there was no marked change or difference between treatment groups in the antral follicle population 24 h after the end of the BMP6 infusion (controls, 6.7 6 0.9 small and 2.3 6 0.2 large; treated, 7.2 6 0.4 small and 2.2 6 0.2 large).
All animals ovulated in response to the LH surge and established a luteal phase. One treated animal had an abnormally high luteal-phase level of progesterone (33 ng/ ml), despite having two morphologically normal corpora lutea 
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on ultrasound. However, when this animal was removed from the analysis, there was no difference between the other treated and control ewes in either the profile of progesterone production during the early luteal phase (data not shown) or the mean value obtained on Day 7 (3.1 6 0.4 ng/ml vs. 2.8 6 0.2 ng/ml in treated and control groups, respectively). Ovulation rate, assessed by ultrasound on Day 7, was not significantly different between treatment groups (2.2 6 0.2 vs. 1.8 6 0.3 in treated and control groups, respectively). The sizes of the corpora lutea formed in treated animals were, however, significantly smaller than in controls (P , 0.01; Fig.  6 ), and retrospective identification of the antral follicles that had ovulated confirmed that the ovulatory follicles measured around the time of the LH surge in each animal were also significantly smaller in treated ewes (P , 0.05; Fig. 6 ).
DISCUSSION
The results of the present study provide strong in vivo evidence that BMP6 acts as a major local regulator of ovarian function in monovulatory ruminants. Taken together, the results show that direct ovarian infusion of BMP6 during the early follicular phase not only results in acute stimulation of ovarian hormone secretion but also has a longer-term effect on the characteristics of the ovulatory follicle population, in that follicles of a smaller size generated sufficient estradiol to induce a precocious LH surge and then go on to form markedly smaller corpora lutea. In this regard, the apparent ability of BMP6 infusion to induce precocious ovulatory follicle maturation resembles the effect of naturally occurring mutations in the BMP system observed in prolific breeds of sheep [38] .
The acute effects of ovarian BMP6 infusion in stimulating ovarian inhibin A, A4, and estradiol production are generally consistent with parallel cell culture studies in this species. Thus, we have been able to demonstrate that BMP6 stimulates a dose-responsive increase in inhibin A and estradiol production by cultured granulosa cells exposed to optimum doses of FSH and IGF1 [21] . Similarly, although BMP6 has been shown to be inhibitory to LH-stimulated androgen production by cultured theca cells at high doses in sheep [21] and cattle [28] , we have also shown that very low doses of BMP6 can stimulate thecal cell proliferation, and hence total A4 production. The timing and transient nature of the changes in ovarian hormone production induced by BMP6 infusion suggest, however, a number of alternative mechanisms for the stimulatory effects observed.
In this experiment, we have observed a transient increase in ovarian inhibin A production, which precedes a similarly transient increase in ovarian A4 production, which precedes a more sustained but still transient increase in ovarian estradiol production. Because inhibin A is known to act as a paracrine factor in stimulating LH-induced androgen production by cultured thecal cells in many species [39] , including the sheep [40] , it is possible that inhibin A is mediating the increase in ovarian A4 production observed after BMP6 infusion, and this then provides androgen substrate for conversion to estradiol by the granulosa cells in which aromatase activity has been stimulated by BMP6 [21] . Further, because inhibin A has also been shown to act as a paracrine factor in stimulating FSHinduced estradiol production by granulosa cells in sheep [40] , it is possible that the increase in estradiol secretion observed after BMP6 infusion may also be mediated, at least partially by inhibin A.
Although the acute increases in ovarian hormone secretion induced by BMP6 infusion were marked, they were transitory, especially inhibin A and A4, which had returned to normal levels within the period of the infusion, whereas estradiol had fallen to control levels within 4 h of the end of the infusion. For inhibin A, which tended to precede A4 and estradiol, it is possible that the transient nature of the response is due to a local negative regulatory mechanism, possibly mediated by the level of follicular androgen and/or estradiol production, and this hypothesis could be tested using existing cell culture models. Alternatively, for both inhibin A and A4 it is possible that the dose of BMP6 infused was initially stimulatory and then with further exposure became inhibitory, and this possibility is supported by the fact that biphasic dose responses to BMP stimulation have been observed in both granulosa [21, 27] and theca cells [21, 28] in vitro. Finally, in terms of A4, it is well established that this androgen is one of the major precursors for aromatization to estrogen in sheep [41] , and therefore it is possible that the decline in ovarian A4 production as estradiol secretion increases in response to BMP6 infusion may also be due to this androgen being converted to estradiol. Similarly, the fall in estradiol secretion after the end of the BMP6 infusion can either be attributed to the cessation of exposure to BMP6 or a possible fall in androgen substrate supply in response to the high dose of BMP6 infused. As illustrated in the individual profile shown in Figure 3 , the fact that the postinfusion fall in estradiol secretion was accompanied by a parallel fall in A4 secretion prior to rapid recovery in the secretion of both steroids leading to the precocious induction of the LH surge tend to support this latter possibility.
From previous studies, the normal time from luteal regression to occurrence of the LH surge in these animals is around 56-64 h [35] , and the vehicle-treated controls in this experiment at 53 h were therefore within the normal range, whereas the time of 43 h observed for treated animals in this experiment was not within the expected range. On the basis of follicle dissection [42] , follicle labeling [43] , follicle ablation [44] and, more recently, ultrasound tracking [35, 45] , it is now generally accepted that in sheep, the presumptive ovulatory estrogenic follicle(s) emerges from a pool of follicles greater than 2 mm in diameter at the time of luteolysis within 10 h of luteal regression, and this was the reason that the 12-to 24-h period after luteal regression was chosen for BMP6 infusion. Although follicle ablation studies have shown that this species has the ability to rapidly promote other follicles into the ovulatory role [44] , the timing and acute nature of the ovulatory response in treated ewes suggest that BMP6 exposure has had a longer-term effect on the existing ovulatory follicle population rather than recruiting a new ovulatory cohort. This conclusion is supported by the lack of endocrine or ultrasound evidence of additional follicular recruitment.
Examination of the endocrine changes around the time of the LH surge showed little difference between treatment groups in the magnitude and profiles of the preovulatory peaks in androstenedione, inhibin A, and estradiol secretion. The absence of any difference in ovulation rate between the treatment groups suggests that this advance in the LH surge is not due to an increase in the number of ovulatory follicles. Rather, the smaller size of the ovulatory follicles and resultant corpora lutea in animals that received BMP6 suggest that this treatment has resulted in precocious maturation of antral follicles, such that follicles of smaller diameter have been able to generate sufficient estradiol to induce an LH surge much earlier than in untreated ewes. It is significant that precocious follicle maturation is also observed in animals carrying the FecB mutation in the BMPR1B receptor [38] , which is one of the receptors through which BMP6 may exert its effects [15] . Thus, it has been well established that FecB mutants have smaller preovulatory follicles with fewer granulosa cells and correspondingly smaller corpora lutea than control ewes [41, 46] , and that these small antral follicles mature precociously, becoming estrogenic and developing LH receptors on the membrana granulosa at diameters of 2.5-3.5 mm, compared with 4-6 mm in non-gene carriers [38, [47] [48] [49] [50] . More recently, we have extended these observations by showing that expression of FIG. 6 . Effect of direct ovarian infusion of BMP6 (open columns; n ¼ 6) in comparison with vehicle-infused controls (closed columns; n ¼ 6) on the diameter of the ovulatory follicle around the time of the LH surge and the diameter and area of the corpora lutea that subsequently formed from these follicles. Because of the occurrence of early LH surges in treated animals, determination of the size of the preovulatory follicle was made by retrospective analysis of videotaped scans using images obtained from the nearest scan performed prior to the LH surge in each animal. Values are mean 6 SEM. *P , 0.05 and **P , 0.01 in relation to vehicle-treated control.
mRNA for both cytochrome P450 aromatase and the b A -subunit of inhibin/activin can be detected in much smaller follicles in FecB mutants compared with controls [51] . This precocious maturation of smaller follicles in FecB mutants means that ovarian estradiol [37, 41, 49] , androgen [37] , and inhibin A [37] secretion during the preovulatory period, as well as luteal progesterone concentrations [38, 52] , do not differ among animals with two, one, or no copies of the FecB mutation. It is therefore highly significant that similar endocrine effects were observed in the present experiment in response to BMP6 infusion, in which smaller ovulatory follicles and corpora lutea resulted in similar levels of follicular and luteal hormone secretion to control animals.
An important distinction, however, between the effects of BMP6 infusion on ovarian function observed in the present study and those observed in FecB mutants is that ovulation rate did not change in this experiment. The ovarian autotransplant, however, is not an ideal model system to examine this parameter because studies can seldom be powered sufficiently to detect meaningful differences in this discrete endpoint. In FecB mutants, it has been calculated that the total population of granulosa cells in estrogenic follicles is identical in the different genotypes, and therefore that the amount of steroid produced per cell does not change, and there are no differences in the timing of endocrine events, including the time of the LH surge [38] . It would therefore be of interest to repeat this experiment and time the period of exposure to BMP6 to the time of the recruitment phase of a follicular wave to see whether effects on both ovulation rate and follicle size can be induced by this treatment.
Although the current experiment supports a role for BMP6 in modulating ovarian function in sheep, the specificity of these actions remains unclear. In contrast to the rat, where fundamental differences in the actions and signaling pathways of BMP6 and BMP7 have been observed [53] , BMP6 has similar effects as BMPs 2, 4, and 7 on cultured sheep [19, 21] and cattle [27, 28] granulosa and theca cells. Glister et al. [27] have reported specific protein expression of BMPs 4 and 7 in isolated bovine theca cells, whereas BMP6 was mainly expressed by granulosa cells and the oocyte. In sheep, in our hands, the only commercially available BMP antibody we found to be specific was one that recognized BMP6, and using this antibody we found extremely strong BMP6 expression in the oocyte and membrane granulosa cell layer and much weaker staining in the theca interna. More recently, Juengel et al. [54] determined mRNA expression for BMPs 2, 4, 6, and 7 in sheep ovaries and reported that although mRNA is detectable by PCR for all these BMPs, only BMP6 was detectable by in situ hybridization, with expression being restricted to the oocyte. Thus, the available evidence supports BMP6 as being a physiological local regulator of ovarian function in sheep, although further work is required to finally confirm the role of other BMPs in regulating ovarian function in this species.
In summary, the results of this experiment data show that direct ovarian infusion of BMP6 results in an acute stimulation in ovarian inhibin A, A4, and estradiol secretion in the absence of any changes in pituitary gonadotropin levels, an advance in the time of the LH surge, and the development of smaller ovulatory follicles and corpora lutea. We conclude that these data support the hypothesis that BMP6 acts as a major local regulator of ovarian function and that alterations in BMP6 cellular signaling may explain some of the effects of the FecB mutation on inducing precocious follicle maturation.
